Proteins that bind to the intracellular expanses, particularly cytoplasmic tail regions, of heptahelical integral membrane receptors are of particular interest in that they can mediate or modulate trafficking or intracellular signaling. In an effort to distinguish new proteins that might promote angiotensin II type 1 (AT 1 ) receptor intracellular events, we screened a yeast 2-hybrid mouse brain library with the rat AT 1A receptor (AT 1 R) carboxyl terminus and identified GABARAP, a protein involved in intracellular trafficking of the GABA A receptor, as a binding partner for the AT 1 R. Interaction of GABARAP with the AT 1 R carboxyl terminus was further substantiated using GST pull-down assays, and binding of the full-length tagged AT 1 R to GABARAP was verified using coimmunoprecipitation. Bioluminescence resonance energy transfer assays further confirmed specific interaction of GABARAP with AT 1 R. Moreover, GABARAP clearly increased the steady-state level of plasma membrane-associated AT 1 R in PC-12 cells. Cotransfection of GABARAP with an AT 1 R fluorescent fusion protein increased PC-12 cell surface expression of the AT 1 R more than 6-fold when standardized to the level of intracellular expression. Furthermore, GABARAP overexpression in CHO-K1 cells engineered to express AT 1 R increased angiotensin II binding sites 3.7-fold and angiotensin II-induced phospho-extracellular signal-regulated kinase 1/2 and cellular proliferation significantly over levels obtained with AT 1 R overexpression alone. In addition, small interfering RNA-mediated knockdown of GABARAP reduced the steady-state levels of the AT 1 R fluorescent fusion protein by 43% and its cell surface expression by 84%. Immunoblot analyses confirmed the quantitative image data. We conclude that GABARAP binds to and promotes trafficking of the AT 1 R to the plasma membrane. (Circ Res. 2008;102:1539-1547.) Key Words: angiotensin receptor Ⅲ AT 1A Ⅲ GABARAP Ⅲ yeast 2-hybrid Ⅲ protein binding Original Figure 7 . Effect of GABARAP on AT 1 R-mediated ERK1/2 activation and cell proliferation. A, CHO-K1 stable double transfectants were serum-starved for 24 hours and then treated with Ang II (10 Ϫ7 mol/L) or vehicle for 10 minutes. Whole cell extracts were subjected to SDS-PAGE and immunoblotting with anti-phospho-ERK1/2 antibodies. The blot was stripped and reprobed with antibody to determine total ERK1/2 levels. B, The ratio of the corresponding phosphorylated and unphosphorylated bands for each treatment was quantified by densitometry (nϭ3). 1 Significantly different from corresponding vehicle at the PϽ0.001 level, 2 significantly different from Ang II treatment of alternate cell line at the PϽ0.001 level. C and D, Growth measurements for CHO-K1 stable transfectants treated with Ang II, losartan (Los), and/or PD123319 (PD), all at 10 Ϫ7 mol/L (nϭ4 experiments [6 replicates per experiment]). 1 PϽ0.001 vs corresponding vehicle, 2 PϽ0.05 vs corresponding vehicle, 3 PϽ0.01 vs Ang II treatment in the alternate cell line.
T he angiotensin (Ang) II type 1 (AT 1 ) and 2 (AT 2 ) receptors are 7-transmembrane G protein-coupled receptors (GPCRs) of the largest GPCR subfamily, family 1, or the rhodopsin-like family. The GPCR superfamily has more than 860 members 1 and more than 50 "GPCR-associated" proteins have now been discovered, the majority of which interact with GPCR cytoplasmic carboxyl termini. 2 Most of these are involved in trafficking, subcellular targeting, and intracellular signaling. Our preliminary studies were designed to identify proteins that bind to the cytoplasmic carboxyl terminus of the AT 1 receptor (AT 1 R), the most prevalent and best characterized of the Ang receptors. Such proteins are expected to be involved in trafficking of the AT 1 R through the secretory pathway and to the plasma membrane, as well as in ligand-mediated internalization and recycling. Moreover, our recent published studies suggest that the AT 1 R is cleaved in a ligand-dependent manner to liberate the cytoplasmic domain, a significant quantity of which traffics to the nucleus. 3 Presumably, this nuclear trafficking event also involves sequence-specific binding proteins. Using a yeast 2-hybrid (Y2H) approach to screen a mouse brain library, we have identified several proteins which bind to the AT 1A R, the most prevalent of which are GABARAP (␥-aminobutyric acid [GABA] receptor-associated protein) and the related protein GABARAPL1 (L1 indicates like-1). Of 40 clones isolated, approximately one-half were identified by sequence analysis, as GABARAP or GABARAPL1, both members of the microtubule-associated protein (MAP) family. GABARAP was originally identified through its binding to one subunit of the pentameric ionotropic GABA A receptor. It is involved in trafficking of the GABA A receptor to the plasma membrane via microtubule tracks and affects both clustering and kinetic properties of the receptor. GABA is the major inhibitory neurotransmitter in the brain and acts through the ionotropic GABA A and GABA C receptors and the metabotropic GABA B receptor. 4 Of these, GABARAP is known to bind only to the GABA A receptor. Postsynaptic binding of GABA to the GABA A receptor opens chloride ion channels and leads to hyperpolarization, thereby slowing neuroelectrical impulses. Coexpression of GABARAP has been shown to increase the level of GABA A receptors detected at the plasma membrane and to cluster recombinant GABA A receptors, [5] [6] [7] [8] the net effect of which is to modulate neuroelectrical inhibition. GABARAPL1 (GEC1), originally identified as an estrogen-induced protein homologous to GABARAP, 9 has since been found to bind to the GABA A receptor 10 and to the carboxyl terminus (C terminus) of the metabotropic -opioid receptor (KOR) and to facilitate receptor trafficking of the KOR from the endoplasmic reticulum/Golgi to the plasma membrane. 11 When expressed in CHO cells, GABARAPL1 coimmunoprecipitates with KOR and greatly increases total and cell surface KOR opioid receptors but notor ␦-opioid receptors. Both of the MAPs, GABARAP and GABARAPL1, therefore, are involved in plasma membrane-directed protein trafficking.
The vital importance of accessory proteins, such as GABARAP, that are involved in intracellular trafficking is exemplified by the development of kidney hypertrophy and hypertension in transgenic mice overexpressing Ang II receptor-associated protein 1 (ARAP1), a protein that is involved in AT 1 R "recycling" in the kidney. 12 The studies described herein were designed to confirm the observed AT 1 R:GABARAP interaction in yeast and to investigate the nature and function of the intermolecular association.
Materials and Methods

Y2H Analysis
An adult mouse brain cDNA library cloned into a GAL4 activation domain vector (pGADT7-Rec) and transformed into yeast strain Y187 was obtained from Clontech (catalog no. 638863) and used for Y2H screening as recommended by the manufacturer.
The AT 1 R C terminus was ligated in-frame into pGBKT7 to produce a Gal4-DBD:AT 1 R C terminus fusion protein. The Y2H target library consisted of mouse brain sequences ligated into pGADT7-Rec to produce Gal4-AD fusion sequences (library from Clontech) (DBD indicates DNA-binding domain; AD, activation domain).
An expanded Materials and Methods section is available in the online data supplement at http://circres.ahajournals.org.
Results
Note that the term GABARAP(X) refers to the combined terms GABARAP and GABARAPL1.
Y2H Screen
A Y2H screen of a mouse brain cDNA library was conducted to identify proteins that interact with the cytoplasmic C terminus of the AT 1A R (amino acids 306 to 359). Of 1.3ϫ10 6 clones screened, 40 clones interacted with AT 1 R as judged by growth on selective media. Sequence analyses revealed that 21 of the 40 recovered clones encoded GABARAP or the related protein GABARAPL1. Both GABARAP and GABARAPL1 (data not shown for the latter) interacted specifically with AT 1 R CT ; interactions with heme oxygenase-1 and biliverdin reductase were not observed in yeast ( Figure 1 ). GABARAP is 87% identical to GABARAPL1 at the amino acid sequence level, whereas GABARAP: GABARAPL2 are 58% identical and GABARAPL1: GABARAPL2 are 61% identical; GABARAPL2 was not recovered from this screening. GABARAP and GABARAPL1 encode very similar proteins belonging to a new MAP family and possess aminoterminal tubulin-binding domains (residues 1 to 27). 13 Not surprisingly, all GABARAP(X) clones recovered from the Y2H screen encode partial proteins (see Figure I in the online data supplement for more information).
GABARAP Interacts With the AT 1 R C-Terminal Cytoplasmic Sequence in Mammalian Cells
The AT 1 R:GABARAP interaction observed in yeast was initially verified in mammalian cells using GST pull-down assays (Figure 2A ). CHO-K1 cells were transiently transfected with pCMV/HA/GABARAP, pGST/AT 1 R CT , or both plasmids, and cell extracts were prepared at 24 hours posttransfection. Extracts were applied to glutathione columns, washed, eluted, and electrophoresed on denaturing gels. Filters were probed with anti-hemagglutinin (HA) antibodies to confirm that AT 1 R CT specifically binds GABARAP. HA-GABARAP clearly associates with GST-AT 1 R CT and is coeluted from the glutathione column.
GABARAP Coimmunoprecipitates With AT 1 R in Mammalian Cell Extracts
CHO-K1 cells were transfected with pFlag/AT 1 R and pCMV/ HA/GABARAP (or empty vector [Ϫ]) or pCMV/HA/ GABARAPL1 (or empty vector [Ϫ]) ( Figure 2B ). Twentyfour hours posttransfection, cell extracts were prepared and immunoprecipitated with anti-Flag antibody or preimmune serum (control) and protein A agarose. The immunoblot was probed with anti-HA antibody. The results indicate that the Flag/AT 1 R interacts with GABARAP and with GABARAPL1 in CHO-K1 cells.
In parallel studies, the intermolecular complexes of HA/ GABARAP:Flag/AT 1 R and HA/GABARAPL1:Flag/AT 1 R were immunoprecipitated with resin-bound anti-Flag antibod- Yeast were cotransformed with plasmids encoding the GABARAP-Gal4 DBD fusion and Gal4 AD fusions of the indicated proteins. Duplicate colonies were resuspended and spotted on nutrient plates lacking leucine and tryptophan (to select for plasmid DNA) or media lacking leu, trp, histidine, and adenine (to select for protein-protein interaction). Yeast expressing AT 1 R CT and GABARAP show complementation. Control proteins heme oxygenase-1 (HO-1) and biliverdin reductase (BvR) do not interact with GABARAP and, hence, do not permit yeast growth on restrictive media.
ies. Resulting immunoblots show that the AT 1 R complexes with GABARAP ( Figure 2C ) and GABARAPL1 ( Figure 2D ) in mammalian cells.
GABARAP Interacts Directly With AT 1 R CT
GST pull-down assays using purified recombinant proteins were carried out to determine whether GABARAP binds directly to AT 1 R CT . As shown in Figure 2E , recombinant GABARAP is eluted from resin charged with the GST-AT 1 R CT fusion but not with GST alone (compare lanes 1 and 3), providing evidence for direct interaction between these proteins.
Bioluminescence Resonance Energy Transfer for GABARAP:AT 1 R Interactions
Bioluminescence resonance energy transfer (BRET) assays ( Figure 3 ) indicate a significant intermolecular interaction between GABARAP and AT 1 R (pGFP 2 /GABARAPϩpAT 1 R/ RLuc), PϽ0.001 versus pAT 1 R/RLuc alone. (Note that all values have been corrected by subtracting the mocktransfected cell background at each emission wavelength, a function of the BRET program.) General negative controls include pAT 1 R/RLuc transfected alone and cotransfected empty vectors (pGFP 2 -C1ϩpRLuc-N1). Experiment-specific negative controls include mouse MAP1 light chain 3 (MAP1 LC3) as a GABARAP analog and the endothelin type A GPCR (ETR-A) as an AT 1 R correlate. The endothelin receptor is from the same GPCR family as the AT 1 R (Family 1, subgroup 1A) and, therefore, serves to show that GABARAP does not promiscuously interact with GPCRs. MAP1 LC3 is a MAP that binds to both MAP1 and MAP2 and, in this case, demonstrates that binding to the Ang receptor C terminus is not a general property of MAPs. Neither the general nor specific negative controls demonstrate significant BRET. The positive control, a commercial vector, pGFP 2 -RLuc, that encodes a cytomegalovirus (CMV)-regulated fusion protein of Renilla luciferase with GFP 2 , has been shown to be expressed at high levels in a variety of cells and, indeed, shows very high energy transfer in our assay (PϽ0.001 versus pAT 1 R/RLuc-transfected; PϽ0.001 versus pGFP 2 / Figure 2. Interaction between GABARAP and AT 1 R. A, GST pull-down assay using the AT 1 R CT . Plasmids expressing the indicated proteins were cotransfected into CHO-K1 cells, and cell extracts were prepared 24 hours later. Five percent of the cell extract was reserved for expression analyses (Input) and the remainder subjected to pull-down reactions. Proteins were separated on SDS-PAGE gels and detected by immunoblotting with the indicated antibodies. B through D, Coimmunoprecipitation with Flag-tagged fulllength AT 1 R. CHO-K1 cells were transiently transfected with plasmids encoding the indicated proteins (ϩ) or the respective empty vectors (Ϫ). B, Cell extracts were incubated with control (IgG) or anti-Flag antibody, followed by immunoprecipitation with protein A agarose. Immunoprecipitates were subjected to SDS-PAGE and transferred to poly(vinylidene difluoride) (PVDF) membrane, and the immunoblot was probed with anti-HA antibody to detect GABARAP or GABARAPL1. The antibody light chain (Ab LC) is indicated. C and D, Cell extracts were incubated with the indicated antibody resin. Immunoprecipitates were subjected to SDS-PAGE and transferred to PVDF membrane, and immunoblots were probed with anti-HA antibodies. E, Direct interaction between GABARAP and AT 1 R CT using purified proteins. GST pull-down assays were performed as described in Materials and Methods using the indicated recombinant proteins. The eluates were subjected to SDS-PAGE and transferred to PVDF membrane. The membrane was probed with anti-GABARAP antibodies, stripped, and subsequently probed with antibody to GST. The GST-AT 1 R CT fusion is highly labile in Escherichia coli, even in BL21 derivatives (the strain used in this study) that lack the lon and ompT proteases. The primary cleavage site appears to be near the fusion junction within the AT 1 R CT sequence, resulting in the purification of two major species by affinity chromatography. The slower migration of the parental GST protein (lanes 3 and 4) relative to the cleaved GST (lanes 1 and 2) is attributable to the contribution of extra amino acids derived from the multiple cloning site downstream of the GST sequence. GABARAPϩpAT 1 R/Rluc). The BRET 2 assays verify and support our Y2H results, GST pull-down assays, and coimmunoprecipitation results. See the online data supplement (expanded Results section) for more information.
Influence of GABARAP Overexpression on AT 1 R Accumulation and Plasma Membrane Presentation
PC-12 neural cells were plated, treated with NGF (7S, 100 ng/mL) for 4 days (to enhance the neuronal differentiation), 14, 15 and then transfected with pAT 1 R/EYFP or pECFP/ GABARAPϩpAT 1 R/EYFP. Cells were evaluated at 24 and 48 hours posttransfection for cell surface expression of AT 1 R/ EYFP using 3D deconvolution microscopy. Under our transfection conditions, AT 1 R/EYFP, as reported in our previous studies, is observed at the plasma membrane but is found predominantly in the secretory pathway (endoplasmic reticulum, Golgi, vesicles) ( Figure 4A1 and 4A2) . By 48 hours posttransfection, GABARAP overexpression increased AT 1 R cell surface expression 6.74-fold when standardized to the level of intracellular expression (PϽ0.005, nϭ3, 100 transfected cells per experiment) ( Figure 4B through 4D ). See the online data supplement (expanded Results section) for more details.
Radioligand Binding Assays
CHO-K1 cells, which do not to express detectable Ang receptor, 16 -18 were stably transfected with AT 1 R/EYFP to obtain a working cell line with a defined Ang receptor. One high-level fluorescent clonal isolate was subsequently transfected with either pECFP/GABARAP or pECFP-C1 (control) and mixed (nonclonal) stable double transfectants were selected. In this manner, the AT 1 R uninduced baseline expression in both double-transfectant lines should be equal. Our studies show that expression of ECFP/GABARAP increases total binding 3.6-fold over the ECFP-C1 control ( Figure 5 ). This increase is sensitive the AT 1 R blocker losartan but not to the AT 2 R blocker PD123319. GABARAP coexpression clearly increases not only the cell surface manifestation of AT 1 R/EYFP (Figure 4 ) but also the number of plasma membrane-associated Ang II binding sites.
Immunoblots
By Western blot analysis, we observed a 7.7-fold AT 1 R protein increase (nϭ3, PϽ0.001) in COS-7 cells transfected with pCMV/myc/AT 1 RϩpCMV/HA/GABARAP as compared with pCMV/myc/AT 1 R with either pCMV/Flag/SNAPAP (control) or control unmodified vectors ( Figure 6 ). Therefore, GABARAP not only alters the distribution but also increases the steady-state AT 1 R protein level.
SNAPAP was included as a negative control in this study. We isolated SNAPAP as a potential AT 1 R binding partner in an initial screen of the Y2H library, but we were subsequently unable to confirm it by affinity pull-down or by coimmunoprecipitation assays. We later learned that SNAPAP (also called SNAPIN) is frequently isolated as a false-positive in initial Y2H assays performed in 2-hybrid service facilities (personal communication, Chandra Tucker, Duke Yeast Model Systems Genomics Group).
GABARAP Effects on Extracellular Signal-Regulated Kinase Activation
Ang II:AT 1 R-mediated extracellular signal-regulated kinase (ERK)1/2 phosphorylation stimulation is known to occur in many cell types and through several mechanisms. 19 -21 Because our imaging data and radioligand binding assays suggest that GABARAP increases plasma membrane accumulation of the AT 1 R, as well as ligand association, we asked whether GABARAP might also (indirectly through increasing plasma membrane accumulation of receptor) stimulate ERK phosphorylation ( Figure 7A and 7B). Our data show that Ang II treatment of pAT 1 R/EYFP stably transfected CHO-K1 cells increases the ratio of phosphorylated to unphosphorylated ERK1/2 levels 2.7-fold over vehicle treatment (nϭ3, PϽ0.005). In comparison, Ang II treatment of pECFP/GABARAP, pAT 1 R/EYFP double-transfectants increases the ratio 5.5-fold (nϭ3, PϽ0.005). GABARAP overexpression, therefore, significantly augments accumulation of phospho-ERK1/2 levels (nϭ3, PϽ0.005), consistent with greater plasma membrane expression of functional AT 1 R in double-transfectants.
Proliferation Assays
Because Ang II has been shown to mediate proliferation of many cell types through the AT 1 R 19,22,23 and our data indicate that GABARAP increases cell surface expression of the AT 1 R, we measured and compared growth of CHO-K1-pAT 1 Ang II increases both 5-bromodeoxyuridine incorporation into DNA and cell counts (3.5-and 3.3-fold, respectively) in the AT 1 R engineered CHO-K1 cell line in a manner that is sensitive to losartan but refractory to PD123319 (Figure 7C  and 7D ). Furthermore, Ang II promotes cell proliferation to a greater extent (approximately 2-fold greater) in the AT 1 R/ GABARAP as compared with the AT 1 R recombinant cell line, consistent with higher plasma membrane expression of functional AT 1 R in these cells.
Small Interfering RNA-Mediated Knockdown of GABARAP Reduces Cell Surface Expression of Recombinant AT 1 R/EYFP
The ability of GABARAP complementary small interfering (si)RNA oligonucleotides to reduce GABARAP protein was tested using hybrid complexes (siGABARAP-1, siGABARAP-2, and siGABARAP-3) made complementary to 3 phylogenetically conserved regions of the mRNA. CHO-K1 cells stably transfected with pECFP/GABARAP and pDsRed2-Nuc were transiently transfected with siRNA du-plexes. Negative control (Silencer #1 from Ambion), and scrambled siGABARAP C -1 negative control caused no diminution in ECFP/GABARAP compared with mocktransfected cells (Figure 8, I) . However, siGABARAP-1, siGABARAP-2, and siGABARAP-3 duplex RNAs all significantly reduced ECFP/GABARAP accumulation, as determined by both deconvolution image analysis (85% to 93% reduction, PϽ0.005 versus scrambled negative control [siGABARAP C -1], nϭ3 experiments/hybrid complex, 100 cells evaluated/experiment) (Figure 8 The GABARAP siRNA duplexes were subsequently applied to CHO-K1 cells stably transfected with pAT 1 R/EYFP and pDsRed2-Nuc to determine whether a reduction in native GABARAP might also diminish fluorescent AT 1 R plasma membrane accumulation. GABARAP siRNAs reduced AT 1 R/ EYFP steady-state levels an average of 43% (PϽ0.005 versus scrambled negative control [siGABARAP C -1], nϭ3 experiments/hybrid complex, 150 cells evaluated/experiment) (Figure 8 , III) and with 84% reduction in plasma membraneassociated yellow fluorescence (PϽ0.01 versus scrambled negative control; SlideBook 4.2 software, "Masks" to quantify regions of interest). Immunoblot analyses were also performed to verify the quantitative image data (Figure 8 , IV). GABARAP siRNA transfection (for any of the 3 hybrid complexes) reduced AT 1 R/EYFP expression an average of 4.2-fold as compared with transfection with scrambled control siRNA (PϽ0.005, nϭ3 experiments).
Discussion
In this report, we show, by 3D deconvolution imaging and radioligand binding, that GABARAP, a MAP involved in GABA A receptor trafficking, increases plasma membrane accumulation of the AT 1 R. We further show that the increase in cell surface AT 1 R correlates, in response to Ang II, with increased phospho-ERK1/2 accumulation and enhanced proliferation. We further demonstrate association of these 2 proteins by yeast complementation, GST affinity pull-down, coimmunoprecipitation assays, and BRET assays. In addition, GABARAP-targeted siRNAs effectively reduce cell surface accumulation of fluorescent AT 1 R, demonstrating the impor-tance of endogenous GABARAP for efficient plasma membrane-directed transport.
Using a similar approach, Dzau and colleagues have discovered that the AT 1 R binds to a transmembrane protein, ATRAP (Ang II type 1 receptor-associated protein), a 162-aa 3-transmembrane protein that modulates Ang II signaling. 24, 25 ATRAP appears to generally downregulate Ang II-mediated AT 1 R function, reducing inositol lipid levels, decreasing Ang II-mediated c-fos transcription, and reducing cell proliferation. ATRAP was isolated from a mouse kidney yeast library using the AT 1A R amino acids 297 to 359 as bait. In contrast, we did not recover ATRAP from a mouse brain yeast library. ATRAP mRNA does appear to be ubiquitous, but it is apparently present at very low levels in brain compared with the levels in kidney, testis, or heart, 25 perhaps accounting for our failure to isolate this message. ATRAP binds to the AT 1 R through the ATRAP C-terminal amino acids 110 to 122. AT 1 R binds to ATRAP through the AT 1 R terminal 20 amino acids (339 to 359).
By further example, using rat AT 1A R amino acids 295 to 359 as bait to screen a mouse 10 day embryo library, Guo et al isolated ARAP1 (type I Ang II receptor associated protein 1), a ubiquitous 493-aa protein that interacts (in rather broad terms) with residues 319 to 359 of the AT 1 R. 26 ARAP appears to enhance receptor recycling to the plasma membrane and receptor resensitization to a second Ang II stimulus. Transgenic mice overexpressing ARAP1 in kidney proximal tubule cells demonstrate high blood pressure and kidney hypertrophy. 12 Therefore, both ATRAP and ARAP1 bind to the distal portion of the AT 1A R C terminus and mediate quite different effects; ATRAP attenuates the Ang II-mediated AT 1 R downstream effects, whereas ARAP1 potentiates Ang II effects by upregulating the receptor level. Both of these also appear to interact with the distal portion of the AT 1 R C terminus. In contrast, our preliminary studies (data not shown) suggest that the binding site for GABARAP is in the membrane proximal region of the AT 1 R cytoplasmic C terminus (proximal to residue 316). Both ARAP1 and GABARAP interactions with AT 1 R appear to serve, in a similar capacity, to upregulate the renin-Ang system.
GABARAP family members appear to be highly connected with binding partners that include NSF (N-ethylmaleimidesensitive factor), 27, 28 tubulin (and microtubules), 4, 29, 30 transferrin receptor, 31 GABA A R, 32-34 AT 1 R, DDX 47 (an RNA helicase), 35 GRIP1 (an adapter and steering protein), 36 gephyrin, 37,38 ULK1 (a neuronal serine/threonine kinase involved in axonal elongation), 39 and p130 (inositol triphosphate binding protein). 40 GABARAP has, in fact, been referred to as a "multifunctional adapter molecule" because of the myriad of binding partners associated with it. 30 The fact that GABARAP is involved in trafficking of both the pentameric ionotropic GABA A R and the 7-transmembrane GPCR AT 1 R suggests that these receptors could be cotransported/coregulated and that conditions that favor upregulation of one may also favor upregulation of the other. This remains to be tested. GABARAP is a ubiquitous protein though it is primarily known for its role in trafficking of the GABA A R in the central nervous system. Our studies indicate that interaction of AT 1 R with GABARAP occurs in nonneuronal cells, although the relative importance of GABARAP for AT 1 R trafficking in neural and nonneural tissue is yet unknown.
Two primary motor proteins control microtubule-based protein transport. Anterograde trafficking (toward the plasma membrane) involves the motor protein kinesin, whereas retrograde movement involves dynein. Kinesin is an ATPbinding protein that "walks" along the length of the microtubule with ATP hydrolysis occurring at each successive 8-nm step. In contrast, GABARAP is not a nucleotidebinding motor protein and does not directly convey the AT 1 Ror GABA A R-containing vesicles to the plasma membrane. Nonetheless, GABARAP increases the steady-state level of these proteins at the plasma membrane. How might GABARAP enhance plasma membrane accumulation of proteins like GABA A R and AT 1 R?
For the AT 1 R, this appears to be, in part, attributable to accumulation of a higher level of receptor as compared with total cell protein in the presence of GABARAP. However, in addition, the trafficking process is altered as established by the change in the distribution of fluorescent AT 1 R when expressed with GABARAP. The relative AT 1 R cell surfaceto-intracellular (secretory pathway) distribution is altered in PC-12 cells overexpressing GABARAP (a cytoplasmic protein). Clearly, GABARAP overexpression causes relatively more AT 1 R accumulation at the plasma membrane compared with the internal compartments. This observation, coupled with the knowledge that GABARAP binds tubulin and microtubules, suggests that GABARAP enhances the transport process. Because GABARAP is not a motor protein and does not actively move vesicular cargo to the plasma membrane, how might it enhance transport? One possibility is that GABARAP increases the processivity of plasma membrane trafficking. A kinesin molecule, on average, completes a 1-m run length before dissociating from a microtubule. 41 Often, cargos must be moved considerably further than 1 m to reach their destination. Therefore, vesicular cargos must be passed from one to another microtubule-engaged kinesin complex to continue processive movement to the plasma membrane. GABARAP could function, therefore, as an accessory protein, binding both vesicle-associated AT 1 R and microtubules, so that AT 1 R containing vesicles are retained on the microtubules, on motor protein dissociation, until the vesicle can be recovered by a second kinesin complex. In this model, GABARAP would bind both vesicle-associated AT 1 R and a microtubule and act as a "rear wheel" stabilizing the kinesin-vesicle complex on the microtubule as it moves the cargo forward. In fact, there does exist evidence to suggest that motors may use secondary binding sites to aid in processivity. 42 Given the central role of the AT 1 R in blood pressure homeostasis and cardiovascular disease, regulation of proteins that are involved in trafficking of this receptor and mechanisms by which these proteins interact with the receptor and modify its accumulation and function are of critical importance. We are the first to report an interaction between the AT 1 receptor and the trafficking protein GABARAP. This novel finding introduces new areas of investigation in the renin-Ang system and in basic mechanisms of Ang IImediated growth and blood pressure control and offers a new potential therapeutic target for pharmacological intervention.
